Combination of etoposide, idarubicin, cyclophosphamide, vincristine, prednisone and bleomycin (VICOP-B) in the treatment of advanced cutaneous T-cell lymphoma

Dermatology

Volumn 194, Issue 3, 1997, Pages 268-272

  Fieno, M T ^a   Doveil, G C ^a   Quaglino, P ^a   Savoia, P ^a   Venone, A ^a   Bernengo, M G ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Antineoplastic agents; Cutaneous T cell lymphoma; Idarubicin; VICOP B regimen

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; IDARUBICIN; PREDNISONE; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; FEMALE; FEVER; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; MYCOSIS FUNGOIDES; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REMISSION; SEZARY SYNDROME; SKIN LYMPHOMA; T CELL LYMPHOMA; THROMBOCYTOPENIA; VOMITING;

EID: 0030961319     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000246116     Document Type: Article

References (20)

1. Sausville EA. Eddy JL. Makuch RW. Fisch-mann AB, Schechter GP. Matthews M, Glat-stein EJ. Ihde DC. Kaye F, Veach SR: Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome: Definition of three distinctive prognostic groups. Ann Intern Med 1988;109:372-382.
2. Grozea PN. Jones SE. McKelvey EM. Coltman CA, Fisher R. Haskins CL: Combination chemotherapy for mycosis fungoides: A Southwest Oncology Group Study. Cancer Treat Rep 1979;63:647-653.
3. Winkler CF. Sausville EA. Ihde DC. Fisch-mann AB. Schechter GP. Kumar PP, Nibha-nupdi JR. Minna JD. Makuach RW, Eddy JL. Bunn PA: Combined modality treatment of cutaneous T cell lymphoma: Results of a 6-year follow-up. J Clin Oncol 1986;4:1094-1100.
4. Hallaban DE. Griem ML, Gricm SF. Medenica M. Soltani K. Lorincz AL. Baron JM: Combined modality therapy for tumor stage mycosis fungoides: Results of a 10-year follow-up. J Clin Oncol 1988:6:1177-1183.
5. Kuzel TM. Roenigk HH. Rosen ST: Mycosis fungoides and the Sézary syndrome: A review of pathogenesis, diagnosis and therapy. J Clin Oncol 1991;9:1298-1313.
6. Holloway KB. Flowers PF, Ramos-Caro FA: Therapeutic alternatives in cutaneous T-cell lymphoma. J Am Acad Dermatol 1992:27: 367-378.
7. Bunn PA. Hoffmann SJ. Norris D. Golitz LE. Aeling JL: Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome). Ann Intern Med 1994:121: 592-602.
8. Diamandidou E, Cohen PR. Kurzrock R: Mycosis fungoides and Sézary syndrome. Blood 1996;88:2385-2409.
9. Case DC. Hajcs DM, Gerber M. Gams R. Ervin TJ, Dorks BM: Phase II study of oral idarubicin in favorable histology non-Hodgkin's lymphomas. Cancer Res 1990;50:6833-6835.
10. Robert J: Clinical pharmacokinetics of idarubicin. Clin Pharmacokinet 1993;2:275-288.
11. Miller AB. Hoogstraten B. Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981;47:207-214.
12. Fisher RI. Gaynor ER. Dahlberg S: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin s lymphoma. N Engl J Med 1983;328:1002-1006.
13. Cooper IA. Wolf MM. Roberston TI, Fox RM. Matthews JP. Stone JM. Ding JC. Dart G. Matthews J. Firkin FC. Lowenthal RM. Ironside P: Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. J Clin Oncol 1994; 12:769-778.
14. O'Reilly SE. Hoskins P, Klimo P: MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease. Ann Oncol 1991;2:17-23.
15. Brugiatelli M. Federico M. Gobbi PG. Avanzini P, Callea V. Cavanna L. De Pasquale A. Di Prisco AU. Di Rienzo N. Silingardi V: Epidoxorubicin vs idarubicin containing regimens, in intermediate and high grade non-Hodgkin's lymphoma: Preliminary results of a multicentric randomized trial. Haematologica 1993:78:306-312.
16. Zinzani PL. Martelli M. Storti S. Musso M. Cantonetti C. Leone G. Cajozzo A. Papa G. lannito E. Perrotti A. Bendandi M. Gherlinzoni F. Gentilini P. Rossi G. Aitini E. Mandelli F. Titra S: Phase III comparative trial, using CHOP vs CIOP in the treatment of advanced intermediate-grade non Hodgkin's lymphoma. Leuk Lymphoma 1995:19:329-335.
17. Kaye FJ. Bunn PA. Steinberg SM. Stocker JL. Ihde DC, Fischmann AB. Glatstein EJ. Schechter GP. Phelps RM. Foss FM. Parlette HL. Anderson MJ. Sausville F.A: A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989:321:1784-1790.
18. Mercieca J. Matutes E. Dearden C, MacLen-nan K. Catovsky D: The role of pentoslatin in the treatment of T-cell malignancies: Analysis of response rale in 145 patients according to disease subtype. J Clin Oncol 1994:12: 2588-2593.
19. Edelson RL. Berger C. Gasparro F. Jegasothy B. Heald P. Wintroub B. Vondherheid E. Knobler R. Wolff K. Plewig G. McKiernan G, Christiansen I. Oster M. Honigsmann H, Wilford H. Kokoschka E, Rehele T. Perez M. Stingl G. Laroche L: Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. N Engl J Med 1987:316: 297-304.
20. Kern WF. Spier CM. Miller TP. Grogan TM: NCAM (CD56)-positive malignant lymphoma. Leuk Lymphoma 1993;12:1-10.